📊 INO Key Takeaways
Is Inovio Pharmaceuticals, Inc.. (INO) a Good Investment?
Inovio Pharmaceuticals faces severe financial distress with collapsing revenues (-70% YoY), massive operating losses (-$86.8M), and negative free cash flow (-$88.9M) indicating the company is burning cash at an unsustainable rate. The company's debt-to-equity ratio of 2.60x combined with only $44.3M in cash against $62.8M in long-term debt creates significant solvency risk, with current operational performance unable to cover debt service obligations.
INOVIO’s fundamentals are very weak: revenue is negligible and shrinking sharply, while operating losses and free cash outflow remain extremely large relative to its asset base and equity. Although net loss and EPS improved year over year, the improvement appears to come off a deeply unprofitable base and does not offset the company’s poor growth quality, leveraged balance sheet, and limited cash runway without stronger commercialization or financing support.
Why Buy Inovio Pharmaceuticals, Inc.. Stock? INO Key Strengths
- Net loss improved 20.8% YoY suggesting margin stabilization from peak losses
- Current ratio of 1.40x provides adequate short-term liquidity cushion
- Positive insider activity with 9 Form 4 filings in last 90 days
- Cash balance of $44.27M still provides some near-term operating flexibility
- Current and quick ratios of 1.40x indicate no immediate liquidity collapse
- Net loss and diluted EPS improved year over year, showing some cost or non-operating loss reduction
INO Stock Risks: Inovio Pharmaceuticals, Inc.. Investment Risks
- Revenue collapsed 70% YoY indicating loss of commercial traction or pipeline setback
- Negative free cash flow of -$88.9M with only $44.3M cash on hand indicates runway of ~6 months at current burn rate
- Debt-to-equity of 2.60x with negative interest coverage (-488.2x) creates imminent debt servicing crisis
- Operating margin of -132,871% reflects extreme unprofitability with minimal revenue relative to operating expenses
- Total liabilities exceed stockholders' equity by $26.1M indicating balance sheet impairment
- Revenue base is extremely small at $65.34K and declined 70.0% year over year, indicating very weak commercialization
- Operating cash flow of -$88.63M and free cash flow of -$88.92M suggest heavy cash burn relative to available cash
- Debt/equity of 2.60x, negative ROE of -352.5%, and long-term debt of $62.76M point to stressed financial health
Key Metrics to Watch
- Cash burn rate and months of cash runway remaining
- Quarterly revenue trends and pipeline advancement
- Debt refinancing ability and covenant compliance status
- Quarterly operating cash burn versus cash and equivalents
- Meaningful revenue growth from product commercialization or partnership inflows
Inovio Pharmaceuticals, Inc.. (INO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Inovio Pharmaceuticals, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
INO Profit Margin, ROE & Profitability Analysis
INO vs Healthcare Sector: How Inovio Pharmaceuticals, Inc.. Compares
How Inovio Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inovio Pharmaceuticals, Inc.. Stock Overvalued? INO Valuation Analysis 2026
Based on fundamental analysis, Inovio Pharmaceuticals, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inovio Pharmaceuticals, Inc.. Balance Sheet: INO Debt, Cash & Liquidity
INO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inovio Pharmaceuticals, Inc..'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-3.95 indicates the company is currently unprofitable.
INO Revenue Growth, EPS Growth & YoY Performance
INO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$19.7M | $-0.87 |
| Q2 2025 | N/A | -$19.7M | $-0.61 |
| Q1 2025 | N/A | -$19.7M | $-0.51 |
| Q3 2024 | N/A | -$25.2M | $-0.89 |
| Q2 2024 | $100.8K | -$30.5M | $-1.19 |
| Q1 2024 | N/A | -$30.5M | $-1.31 |
| Q3 2023 | $388.4K | -$33.9M | $-0.13 |
| Q2 2023 | $226.0K | -$35.5M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inovio Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
INO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inovio Pharmaceuticals, Inc.. (CIK: 0001055726)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INO
What is the AI rating for INO?
Inovio Pharmaceuticals, Inc.. (INO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INO's key strengths?
Claude: Net loss improved 20.8% YoY suggesting margin stabilization from peak losses. Current ratio of 1.40x provides adequate short-term liquidity cushion. ChatGPT: Cash balance of $44.27M still provides some near-term operating flexibility. Current and quick ratios of 1.40x indicate no immediate liquidity collapse.
What are the risks of investing in INO?
Claude: Revenue collapsed 70% YoY indicating loss of commercial traction or pipeline setback. Negative free cash flow of -$88.9M with only $44.3M cash on hand indicates runway of ~6 months at current burn rate. ChatGPT: Revenue base is extremely small at $65.34K and declined 70.0% year over year, indicating very weak commercialization. Operating cash flow of -$88.63M and free cash flow of -$88.92M suggest heavy cash burn relative to available cash.
What is INO's revenue and growth?
Inovio Pharmaceuticals, Inc.. reported revenue of $65.3K.
Does INO pay dividends?
Inovio Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find INO SEC filings?
Official SEC filings for Inovio Pharmaceuticals, Inc.. (CIK: 0001055726) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INO's EPS?
Inovio Pharmaceuticals, Inc.. has a diluted EPS of $-1.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Inovio Pharmaceuticals, Inc.. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INO stock overvalued or undervalued?
Valuation metrics for INO: ROE of -352.5% (sector avg: 15%), net margin of -130,000.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INO stock in 2026?
Our dual AI analysis gives Inovio Pharmaceuticals, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INO's free cash flow?
Inovio Pharmaceuticals, Inc..'s operating cash flow is $-88.6M, with capital expenditures of $285.7K. FCF margin is -136,074.5%.
How does INO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -130,000.0% (avg: 12%), ROE -352.5% (avg: 15%), current ratio 1.40 (avg: 2).
Is Inovio Pharmaceuticals, Inc.. carrying too much debt?
INO has a debt-to-equity ratio of 2.60x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.40 suggests adequate short-term liquidity.